These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17900371)

  • 41. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension.
    Bournias TE; Lee D; Gross R; Mattox C
    J Ocul Pharmacol Ther; 2003 Jun; 19(3):193-203. PubMed ID: 12828838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure.
    Cheng JW; Wei RL
    Clin Ther; 2008 Apr; 30(4):622-32. PubMed ID: 18498911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study.
    Cellini M; Caramazza R; Bonsanto D; Bernabini B; Campos EC
    Ophthalmologica; 2004; 218(5):312-7. PubMed ID: 15334011
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.
    Gandolfi S; Simmons ST; Sturm R; Chen K; VanDenburgh AM;
    Adv Ther; 2001; 18(3):110-21. PubMed ID: 11571823
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N; Sahin A; Gultekin S
    J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study.
    Konstas AG; Holló G; Irkec M; Tsironi S; Durukan I; Goldenfeld M; Melamed S
    Br J Ophthalmol; 2007 Jun; 91(6):757-60. PubMed ID: 17124241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Robin AL
    Am J Ophthalmol; 2003 Jun; 135(6):921-2; author reply 922-3. PubMed ID: 12788149
    [No Abstract]   [Full Text] [Related]  

  • 51. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
    Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.
    Ota T; Aihara M; Narumiya S; Araie M
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; Hoop J; Morgan L; Wudunn D; Catoira Y;
    Br J Ophthalmol; 2006 Nov; 90(11):1370-3. PubMed ID: 16825272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Bimatoprost therapy in glaucoma].
    Călugăru D; Călugăru M
    Oftalmologia; 2009; 53(3):34-45. PubMed ID: 19899545
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination.
    Centofanti M; Oddone F; Gandolfi S; Hommer A; Boehm A; Tanga L; Sangermani C; Sportelli V; Haustein M; Manni G; Rossetti L
    Am J Ophthalmol; 2010 Oct; 150(4):575-80. PubMed ID: 20688314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
    García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
    Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects.
    Halpern MT; Covert DW; Robin AL
    Trans Am Ophthalmol Soc; 2002; 100():109-17; discussion 117-8. PubMed ID: 12545683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC; Vold S; Williams JM; Hollander DA
    Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.
    Day DG; Schacknow PN; Sharpe ED; Ellyn JC; Kulze JC; Threlkeld AB; Jones ED; Brown RH; Jenkins JN; Stewart WC
    J Ocul Pharmacol Ther; 2004 Oct; 20(5):383-92. PubMed ID: 15650513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.